Trial Designs For Non-Metastatic Prostate Cancer On Oncologics Advisory Committee Agenda
This article was originally published in The Pink Sheet Daily
Executive Summary
Men who have no metastases yet their PSAs are climbing after androgen-depravation therapy need new treatment options, FDA maintains, while clinicians may argue what they need is better quality imaging.